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Abstract. Liposomes, the artificial phospholipid vesicles, have the capacity of entrapping
water soluble substances in their aqueous compartments. Of the many possible potentials of 
liposomes their application in immunology is most significant. Recent studies have shown an 
adjuvant and a carrier effect of liposomes to a number of antigens. Liposomes used in these 
studies are generally multilamellar vesicles with the antigen encapsulated in the aqueous phase. 
Some antigens may also be associated with the lipid lamellae covalently or noncovalently. The 
adjuvant property of liposomes is greatly affected by the surface charge of the vesicle as well as 
the site of association of the antigen. The other factors which may have a role in 
immunopotentiation by liposomes are the size and structure of the vesicles, the lipid 
composition, route of administration and their surface sugars. In addition, liposomes may 
function as carriers to haptens and other antigens. In association with liposomes the nature of 
the immune response may be modulated. For a further enhancement of the adjuvant activity of 
liposomes use has been made of immunomodulators.
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Introduction 
 
Liposomes are artificial vesicles comprised of lipid and aqueous compartments where 
the lipid exists in the bilayer form. Such vesicles can be composed solely of 
phospholipids or in combination with other amphipathic molecules such as sterols, 
long chain organic bases or acids. When phospholipids are suspended in an excess of 
aqueous solution they spontaneously form multilamellar concentric bilayers with lipid 
layers separated by layers of aqueous medium. Water soluble substances such as drugs, 
proteins, nucleic acids and dyes, present in the aqueous phase during the formation of 
liposomes, can be encapsulated into the aqueous compartments of the vesicles. This 
unique property of liposomes has made them a versatile tool for an increasing number 
of studies in biology and medicine.
The earliest suggestion of a therapeutic potential for liposomes was for its possible 
application as carriers of enzymes and drugs in vivo in the therapy of various metabolic 
and physiological disorders (Gregoriadis et al., 1971). The concept behind the use of 
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albumin; GCSA, gross cell surface antigen; ULV, unilamellar vesicles; DPPC, dipalmitoyl phosphatidyl- 
choline; DSPC, distearyl phosphatidylcholine; MDP, muramyl dipeptide; MAF, macrophage-activating 
factor. 
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liposomes as carriers of drugs and macromolecules was mainly related to an expected 
protection of the encapsulated molecules in the blood stream. On the contrary, it was 
found that liposome encapsulation of antigens resulted in elevated antibody titres in 
comparison to the free antigen (Allison and Gregoriadis, 1974). This interesting 
observation opened the field for the study of the immunopotentiating properties of 
liposomes. The common adjuvants used for experimental immunization in laboratory 
animals are Freund’s complete and incomplete adjuvants (CFA and IFA). They are 
composed of a water-in-oil emulsion with or without heat killed mycobacteria. Though 
these adjuvants evoke high level and long lasting immunity they are not suitable for use 
in humans since they cause the formation of granulomas at the site of injection. Other 
adjuvants such as alum, aluminium hydroxide and calcium chloride used in humans are 
far from ideal. Hence, a need is felt for a safe and effective adjuvant for use in human 
immunization. Liposomes have a decided advantage over the above mentioned 
adjuvants since they are prepared from biodegradable phospholipids which do not 
produce granulomas (Allison and Gregoriadis, 1976). Further, liposomes protect the 
entrapped antigens from the hypersensitivity reactions (Gregoriadis and Allison, 1974). 
The adjuvant and carrier property of liposomes to a number of antigens has been 
established in recent years (van Rooijen and van Nieuwmegen, 1981; Alving and 
Richards, 1983). Considering the potential of liposomes in immunopotentiation it is 
likely that their application in this field may be realized first.
In addition to the development of liposomes as immunopotentiators, the vesicles 
have been used earlier in investigating a wide range of immunological events. These 
include lysis of foreign cells as a consequence of membrane damage and the ability of 
membrane sensitized haptenic antigens to induce formation of antibodies and/or 
cytotoxic effector cells. In the present review attention will be directed to the adjuvant 
properties of liposomes with respect to protein antigens and as carriers of haptens.
 
Preparation of liposomes 
 
Liposomes generally used in the immunological studies are multilamellar in structure. 
The ease of encapsulation of proteins and haptenic groups and the variety of lipid 
compositions used in the preparation of multilamellar vesicles (MLVs) makes them the 
choice for these studies. The method described by Bangham et al. (1974) for the 
preparation of MLVs is exceptionally simple. The lipid mixture taken in organic 
solvents is allowed to deposit upon the walls of a round bottomed flask by rotary 
evaporation under reduced pressure. The thin film of lipids is dispersed in aqueous 
buffer at a temperature above the transition temperature (Tc) of the lipid or above the Tc 
of the highest melting component in the mixture.
A higher percentage of encapsulated aqueous phase per mol of lipid may be achieved 
by a long hydration and gentle shaking than a faster and vigorous preparation. The 
entrapped volume of the MLVs can be further increased by including charged lipids in 
the bilayer. The main disadvantages of MLVs are the heterogenous population of 
vesicles and relatively low ratio of internal aqueous space per total lipid. A more 
uniform preparation can be obtained by passing the vesicles through polycarbonate 
membrane (Olson et al., 1979) or by extrusion through a French Press (Barenholz et al., 
1979). 
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Association of materials with liposomes 
 
The original and still most commonly used mode of association of materials with 
liposomes is the aqueous phase entrapment of water soluble molecules. However, 
macromolecules such as proteins during entrapment in the aqueous phase may bind to 
the surface of liposomes (Tyrrell et al., 1976). This is similar to membrane-protein 
interaction which may be electrostatic or hydrophobic in nature. Such a preparation 
results in antigens exposed on the surface of liposomes. For a specific surface 
expression of antigens, preformed liposomes are incubated with the protein (Raphael 
and Tom, 1984). For an incorporation of the materials in the lipid bilayers the nonpolar 
molecules are added to and dried down with the lipid phase in organic solvent 
(Bangham et al., 1974). The higher the solubility of the molecules in the non-polar 
solvent the greater the amount which can be sequestered in the hydrophobic regions of 
the liposomes. A more stable surface expression of antigens is obtained by covalent 
coupling of these molecules to preformed liposomes. Four general methods have been 
described in literature for the coupling of proteins to the surface of liposomes.
 
Periodate oxidation of visinal cis-hydroxyl groups of oligosaccharide chains of glyco- 
proteins followed by reduction of Schiff’s bases formed between the amino groups of the 
phospholipids of the liposomes 
 
For example, horse raddish peroxidase has been covalently coupled to preformed 
liposomes containing phosphatidyl ethanolamine, stearylamine or phosphatidyl serine 
(Heath et al., 1980). The major disadvantage of this method is that it can be applied for 
coupling of only those proteins having available oligosaccharide residues for the 
generation of aldehydes. However, in recent years a number of novel methods have 
been developed for glycosylation of proteins. This method may then be applied for the 
glycosylated proteins.
 
Periodate oxidation of the oligosaccharide chains or glycosphingolipids of liposomes 
followed by reduction of the Schiff’s bases formed between the amino groups of the proteins
and aldehyde groups of the lipid 
 
In this way proteins such as immunoglobulins and F(ab′)2 fragments have been 
covalently coupled to vesicles (Heath et al., 1981). This method, too, has a disadvantage 
as it necessitates the presence of glycosphingolipids in the liposome membrane.
 
Homobifunctional cross linking between the amino groups of phospholipids and proteins 
mediated by glutaraldehyde, dimethyl suberimidate or carbodiimide
 
Torchilin et al. (1978) used these coupling agents and a stable immobilization of α- 
chymotrypsin on the surface of liposomes was achieved. However, utilization of 
homobifunctional coupling agents might lead to the formation of homopolymers of 
vesicles, protein or both. 
 
Chemical cross linking using heterobifunctional agents 
 
In order to minimize homopolymerization and intramolecular cross linking the use of 
heterobifunctional agents has been suggested. An example of such a reagent is N- 
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hydroxyl-succinimydl β-(2-pyridyldithiopropionate) (SPDP) for covalent coupling of 
antibody and S. aureas protein A to liposomes (Laserman et al., 1980). For coupling of 
protein to liposomes SPDP is first reacted with phosphatidylethanolamine and the 
stable derivative PE-DTP is used for the formation of the liposomes. Subsequently, 
proteins containing activated thiol, groups are coupled to the liposomes. A similar 
method, introduced by Martin and Paphadjopoulos (1982) involves the formation of a 
phospholipid derivative N-[4-(p-maleimidophenyl) butyryl] phosphatidyl ethanol-
amine. The maleimide moiety incorporated in liposomes is reacted with the sulphydryl 
groups of F(ab′) fragments leading to an efficient and stable protein-vesicle linkage. 
Recently a modified method involving thiolation of antigen and coupling to maleimide 
moiety of preformed liposomes has been described for proteins lacking sulphydryl 
groups (Shek and Heath, 1983).
Haptens such as lipids and peptides are incorporated in liposomes by covalently 
coupling them to phsophatidylethanolamine prior to liposome preparation. This 
method of liposome sensitization has been found to enhance the immuno-genicity of a 
wide variety of agents (Kinsky, 1980; van Houte et al., 1981).
 
Adjuvant Properties of liposomes 
 
The adjuvant effect of liposomes was first reported by Allison and Gregoriadis (1974) 
for the antigen, diptheria toxoid. Since then the immunopotentiating effect of 
liposomes has been the subject of an increasing number of studies. The immunogenicity 
of a wider variety of antigens for example proteins (van Rooijen and van Nieuwmegen, 
1980b; Heath et al., 1976), peptides (Liftshitz et al., 1981), sugars (Das et al., 1982a,b) 
and lipids (Alving, 1977) have been found to be significantly enhanced in association 
with liposomes. 
The properties of the liposomes may be varied at will. For instance the vesicle size 
phospholipid composition, surface charge and lamellar structure may be altered as 
desired. As a consequence, the immunopotentiating capacity of the vesicle to the 
associated antigen also changes. A number of parameters affecting the adjuvant 
property of liposomes have been studied in the past decade which is discussed below. 
 
 
The effect of surface charges of the vesicles 
 
Liposomes may be neutral, negative or positvely charged depending on the lipid used in 
the liposome preparation. The effect of surface charge on the immunopotentiating 
activity of liposomes was first observed by Allison and Gregoriadis (1974). It was found 
that inoculation of diptheria toxoid in negatively charged liposomes elicited signifi- 
cantly higher antibody levels than when entrapped in neutral or positively charged 
liposomes. A later report showed that though negatively charged liposomes could act as 
adjuvants, positively charged liposomes too could do the same (Heath et al., 1976). 
Similar results were obtained by van Rooijen and van Nieuwmegen (1980b) showing 
that positively charged and neutral liposomes have the same adjuvant activity as 
negatively charged liposomes. Still most of the workers studying the adjuvant 
properties of liposomes to antigens made use of negative liposomes. Recently the 
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effectiveness of positively charged liposomes in producing significant levels of 
antibodies has been demonstrated (Latif and Bachhawat, 1984a). The antibody titres 
obtained with lysozyme entrapped in positively charged liposomes has been found to 
be higher than neutral, negatively charged liposomes and even CFA. The high level of 
immunopotentiation by positive liposomes cannot be attributed to a higher affinity of 
the antigen for these liposomes since both carry the same charges. In contrast to 
previous reports that liposomes do not cause granuloma formation (Allison and 
Gregoriadis, 1976) it was found that positively charged liposomes, with or without 
antigen, lead to the formation of mild granulomas at the sites of injection. Though the 
exact mechanism of action of the positively charged liposomes is not understood, it is 
clear that these liposomes interact differently with cells in vivo in comparison to the 
neutral and negatively charged liposomes possibly eliciting a cell-mediated immunity, 
in addition. There is a possibility that the positive charge may hamper the fusion of the 
vesicles with the lysosomes thus allowing protection and prolonged exposure of the 
entrapped antigen to the immune system. Further studies on the interaction of 
liposomes with cells in culture may provide an insight into the mode of action of these 
vesicles. For the present, the profound immunopotentiating activity of positively 
charged liposomes is of considerable interest.
 
Table 1. Antibody response of rabbits to lysozyme 
 
 
* Subcutaneous injections of lysozyme administered at 0, 2 and 4 weeks. 
** Sera assayed by passive haemagglutination and expressed as the reciprocal dilution of the end point. Each 
datum point represents the mean response of three animals. 
† Latif and Bachhawat, 1984a.  
§ Latif and Bachhawat, 1984b. 
|| Latif, 1984. 
ND Not done. 
 
The effect of the sites of association of the antigen with the liposome vesicles
 
As discussed earlier there are a number of ways by which proteins can be associated 
with liposomes and this depends upon the physicochemical properties of the proteins. 
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Water-soluble molecules may be entrapped within the aqueous compartments between 
the lipid lamellae whereas hydrophobic proteins may interact with the lipid bilayers 
(Tyrrell et al., 1976). Further, amphipathic substances may be associated with the lipid 
bilayers; at the same time their hydrophilic tails may project on the surface of the 
liposomes (Fendler, 1980). Recent interest has been centred on the effect of the modes of 
association of antigen with liposomes on antibody production. Entrapment of a variety 
of antigens in liposomes has been found to induce enhanced humoral responses 
compared to similar proteins injected free in saline (Allison and Gregoriadis, 1974; van 
Rooijen and van Nieuwmegen, 1977; Hudson et al., 1979). That a liposome protein 
association was a prerequisite for the adjuvant effect was evident when mixtures of free 
antigen and liposomes did not lead to any immune stimulation (Shek and Sabiston, 
1982b). During encapsulation in liposomes some antigens for example serum proteins, 
may associate with the liposome surface membrane (Hoekstra and Scherphof, 1979). 
Conflicting reports have appeared regarding the significance of surface exposure (van 
Rooijen and van Nieuwmegen, 1980a) versus internal entrapment (Six et al., 1980) of 
the antigen in enhancing the immunogenicity of liposome-associated antigens.
Van Rooijen and van Nieuwmegen (1977, 1978) reported comparable anti-body 
titres elicited by human serum albumin and bovine γ-globulin adsorbed on and 
entrapped within the liposomal vesicles. Subsequently it was postulated that only those 
ligands that are exposed on the liposome surface are immunogenic. However, 
substantial data to prove or disprove this hypothesis was lacking. On the contrary 
internalizing of a number of antigens in liposomes was reported to induce antibody 
production (Allison and Gregoriadis, 1974; Hudson et al., 1979). The significance of 
surface adsorbed and entrapped antigens in mediating immune responses has been 
further investigated using bovine serum albumin (BSA) and another serum protein 
(Shek and Sabiston, 1982b). It has been found that antigens exposed on the surface of 
liposomes are immunogenic. At the same time trypsinization of liposome encapsulated 
antigens does not reduce or abolish the immunological response. Additional informa- 
tion regarding the immunogenicity of entrapped antigen has been obtained using 
lysozyme as an antigen (Latif, 1984). Lysozyme does not associate with the liposome 
surface and as such it leads to almost negligible antibody production. However, when 
entrapped in liposomes the antibody titre is highly significant.
Viral antigens are mostly membrane proteins and when incorporated in liposomes 
may associate with the aqueous compartments as well as the lipid membranes. Such a 
polypeptide derived from Hepatitis Β surface antigen showed a high percentage of 
incorporation in liposomes (Sanchez et al., 1980). When administered in guinea pigs 
higher antibody titres were obtained with liposome-associated antigen than the antigen 
administered in aluminium gel. Similarly, gross cell surface antigen (GCSA), extracted 
from syngenic (C58NT)D lymphoma cells and incorporated in liposomes showed a 
strong association with the lipid membranes and only 25 % of the total protein was 
trapped in the aqueous compartment. Immunization with liposome-associated GCSAa 
showed that the antigen present on the liposome surface could induce antibodies to 
GCSAa reaching in some instances the level obtained after immunization with viable 
syngenic tumour cells (Gerlier et al., 1980). The immunogenicity of surface expressed 
antigens has been further demonstrated using human LS174T colon tumour cell 
membranes incorporated in vesicles (Raphael and Tom, 1984).
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Proteins, as described earlier could be associated with the liposomes by covalent 
linkage with the vesicles. However, the effect of such an association on immunopoten- 
tiation by liposomes has not been extensively investigated. Recently this phenomenon 
for enhancing the immunogenicity of BSA has been employed by Shek and Heath 
(1983). BSA covalently linked to the surface of preformed unilamellar vesicle composed 
of phosphatidyl choline, cholesterol and N-(4-maleimidophenyl butyryl) phosphatidyl 
ethanolamine has been found to be immunogenic. A simpler method for coupling 
lysozyme to liposomes through phosphatidyl ethanolamine has been carried out earlier 
(Latif and Bachhawat, 1981). The surface-coupled antigen has been found to be 
significantly immunogenic. However, in association with another adjuvant, CFA 
coupled ligands are several fold more immunogenic than the native antigen in CFA 
(Latif, 1984). These studies demonstrate the potential of liposomes as carriers and 
adjuvants to protein antigens and may find application in vaccine preparation.
 
Effect of size and structure of liposomes 
 
The size and structure of liposomes may be modulated as required. It is anticipated that 
these factors may affect the immunogenicity of liposome associated antigens. However, 
comparative studies of the immunogenicity of antigens associated with different 
preparations of liposomes are not available. Most of the immunological studies on 
liposomes have been carried out using MLVs. Recently the differences in multilamellar 
and unilamellar liposomes of comparable size in promoting antibody response to a 
protein antigen has been analyzed (Shek et al., 1983). Results obtained with the 
negatively charged liposomes prepared from dimyristoyl-lecithin indicate that uni- 
lamellar vesicles (ULVs) are more effective than MLVs in promoting an immune 
response to the entrapped BSA. Though the exact mechanism responsible for the 
difference in the immunopotentiating capacity of the two liposome preparations 
remains to be established, it is postulated that the extent of BSA molecules embedded in 
the phospholipid bilayers of the two kinds of vesicles might have a role to play.
 
Effect of lipid composition 
 
Most of the liposomal vesicles for immunological studies have been prepared from egg 
lecithin, cholesterol and a negatively charged phospholipid, diacetyl phosphate or 
phosphatidic acid. In order to introduce a positive charge stearylamine is used. The 
molar ratio of the lipids used in the preparation of liposomes which promotes effective 
antibody production (Allison and Gregoriadis, 1974) is usually 7:2:1 of egg leicthin, 
cholesterol and charged lipid, respectively. However, whether this ratio is indeed 
optimum for immune enhancement remains to be established.
Egg lecithin or phosphatidylcholine is the most important ingredient of liposomes 
used for adjuvant activity. It is bio-degradable and a harmless compound when 
administered as liposomes (van Rooijen and van Nieuwmegen, 1980b) although some 
exchange may occur with the phopholipid of cells (Gregoriadis et al., 1977). The most 
important advantage of phosphatidylcholine liposomes as adjuvants is that, in contrast 
to phosphatidyl inositol, phosphatidyl glycerol and phosphatidic acid, phosphatidyl- 
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choline is a very poor antigen (Alving, 1977). Liposomes prepared with phos- 
phatidylcholine by themselves, do not evoke an immune response in rabbits even when 
incorporated in IFA. However an immune response against phosphatidylcholine is 
induced when lipid A is incorporated in the liposomes (Shuster et al., 1979).
Liposomes prepared from sphingomyelin have been reported to be more effective in 
eliciting an immune response to incorporated antigen than liposomes from phsopha- 
tidylcholine (Uemura et al., 1974; Yasuda et al., 1977). There is a striking difference in 
the Tc of these lipids (Phosphatidylcholine –8° to 15°, sphingomyelin 42°) and it is 
suggested that high immunological response by sphingomyelin liposomes may be due 
to their greater stability. In contrast to these observations van Rooijen and van 
Nieuwmegen (1980b) reported lower adjuvant activity of sphingomyelin liposomes 
than phosphatidylcholine liposomes to the associated protein antigen.
Liposomes composed of dipalmitoyl phosphatidyl-choline (DPPC) and distearyl 
phosphatidylcholine (DSPC) (Tc 41·4° and 54·9°, respectively) have also been reported 
to be more effective immunogens than those prepared from egg lecithin (Hudson, 
1977). It is postulated that these liposomes may have greater bilayer stability at 
physiological temperature and may thus persist longer in vivo than egg lecithin. In 
contrast, it has been found that though DPPC and DSPC liposomes are strong 
immunopotentiators to the entrapped antigens liposomes prepared from egg lecithin 
are better adjuvants (Latif and Bachhawat, 1984a).
 
Effect of the route of administration
 
For potentiating an immunological response to liposome-associated antigens, animals 
may be immunized intravenously, intraperitoneally, intramuscularly or subcu- 
taneously. A strong primary immune response is induced by intravenous administra- 
tion of liposome-associated antigens (Allison and Gregoriadis, 1974; Heath et al.,1981). 
However, the response does not persist and may not show a secondary induction. In 
contrast, intramuscular and subcutaneous route elicit higher concentration of anti- 
bodies (Allison and Gregoriadis, 1974; Heath et al., 1976) on secondary immunization. 
Intraperitoneal injections of liposome-associated antigens too, induce a substantial 
antibody production (Shek and Sabiston, 1982a,b).
After intravenous injection liposomes are removed from the circulation by 
reticuloendothelial cells and are rapidly degraded (Tyrrell et al., 1976). Thus 
accumulation of liposomes in order to trigger a high antibody response does not take 
place. Still, significantly higher titres of anitbody were obtained after intravenous 
administration of liposome entrapped antigen that the free foreign protein (Allison and 
Gregoriadis, 1974; Hudson et al., 1979). The adjuvant property of intravenously 
administered liposomes is evident from the observation that liposome carrier itself 
could activate phagocytic cells in the reticuloendothelial system (Hudson et al., 1979). 
Significant stimulation of the immune system is observed when liposomes are injected 
subcutaneously intramuscularly or intraperitoneally. It is possible that liposomes 
injected by these routes will remain at the site of injection for a long period. Thus 
liposomes exert their adjuvant effect by retaining a ‘depot’ of an antigen at the site of 
injection (Tyrrell et al., 1976). However, the adjuvant action is not entirely physical. 
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Some interaction between liposome and cells of the immune system has been reported 
(Hudson, 1977). The appearance of activated mononuclear phagocytes and increased 
specific activities of several lysosomal hydrolases in these cells by a single liposomal 
sensitization in mice (Hudson et al., 1979) indicates that liposomes may affect the 
reticuloendothelial function directly by activating phagocytic cells.
 
The effect of sugars on the surface of liposomes
 
Most adjuvants exert their major effects in macrophages (Allison, 1979). However, the 
mechanism of cellular action of liposomes in stimulating antibody production remains 
to be established. It is clear that liposomes administered either intravenously, 
intraperitoneally or subcutaneously are sequestered by the organs of high reticulo- 
endothelial activity such as liver, spleen, lymph nodes (Tyrrell et al., 1976). Thus they 
finally gain access to the phagocytic cells of the reticuloendothelial system which are 
responsible for the clearance of the liposomes. However, the participation of these cells 
i.e., the macrophages, in potentiating the immune response to liposome-associated 
antigens remains unresolved. Recently it has been shown that macrophages are 
necessary for the induction of a humoral response to lipsome-associated protein 
antigens (Shek and Lukovich, 1982). Liposomes designed specially to interact with 
macrophages would facilitate a better immunopotentiation. It is well established that 
macrophages possess recognition sites for sugars such as mannose, galactose and 
fucose (Weir, 1980). Liposomes carrying terminal galactose and mannose residues are 
specifically recognized by lecithin-like molecules present on the plasma membranes of 
macrophages of parenchymal and nonparenchymal tissues (Ghosh and Bachhawat, 
1980). A recent study of the immunological response of sugar grafted liposomes shows 
that antigen entrapped liposomes bearing galactose on the surface induce an immune 
response comparable to sugar-free neutral liposomes. However, the immune response 
by mannose-coupled liposomes is alsmost equal to that of the free antigen (Latif and 
Bachhawat, 1984b). Based on these results, it is postulated that subcutaneous 
administration of liposomes facilitates a receptor mediated uptake by peritoneal 
macrophages and macrophages derived from bone marrow by a recognition system 
specific for mannose. A greater accessibility of these liposomes to the phagocytic cells 
leads to a rapid degradation of the antigen and subsequently low immune response 
results. 
 
Liposomes as carriers of antigens 
 
In addition to their adjuvant effect, liposomes have been recognised as efficient carriers 
of antigens in recent years. Haptenic groups are generally inserted in liposomes by 
coupling them to one of the phospholipids used in the liposome preparation. With such 
liposomes, Kinsky (1978) investigated the immune response of haptens such as 
dinitrophenyl and phosphorylcholine. The most obvious advantages of the use of 
liposomes as carriers are the easy biodegradability and the low immunogenicity of 
liposomes compared to protein carriers thus eliminating the need to remove carrier 
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specific antibodies. These potentials of liposomes attracted extensive research in the 
production of antibodies to a number of haptens.
This approach for obtaining specific antibodies has been extended to molecules of 
clinical interest such as hormones, drugs, vitamins etc. For example, anti-L-thyroxine 
antiserum has been produced with liposomes sensitized with L-thyroxine derivative of 
phosphatidylethanolamine (Tan et al., 1981). In addition, extensive studies on the 
immunogenic properties of haptenated liposomes have been carried out using 
tripeptide enlarged haptens such as 3-(p-azobenzene arsonate)-N-acetyI-L- 
tyrosylglycylglycine and N-(2,4-dinitrophenyl)-β-alanylglycylglycine (van Houte et al., 
1981). Wood and Kabat (1981) showed the production of antiglycolipid antibodies and 
Das et al. (1982a,b, 1984) report the production of antibodies against sugars such as 
mannose, galactose and N-acetyl-D-glucosamine using liposomes as carriers. The 
carrier effect of liposomes to protein antigens has also been reported (Latif, 1984).
 
Nature of the immune response mediated by liposomal antigens
 
For a better understanding of the mechanism of adjuvant action of liposomes to 
associated antigens and for their applicability in vaccines, information regarding the 
kind of immunoglobulin produced by liposomal antigen is required. Protein antigens 
are generally T-dependent with respect to eliciting antibody production and in 
association with liposomes their humoral response is not altered (Shek and Sabiston, 
1982a; Latif, 1984). However, these reports are at variance with the study of van Rooijen 
and van Nieuwmegen (1983) who found IgM antibodies produced during primary 
immunization of BSA associated with liposomes. BSA molecules are associated with 
the liposome surface and it is possible that the surface-association is responsible for the 
observed IgM response. Haptens such as tripeptides (van Houte et al., 1981) and sugars 
such as N-acetyl-D-glucosamine (Das et al., 1984) and galactose (Sarkar and Das, 1984) 
result in the formation of 1 gM type of antibodies. Though this difference in the kind of 
antibody produced cannot be resolved at present it may be possible that the type of 
antigen has a significant role to play.
 
Liposomes as carriers of additional immunomodulators
 
The immunoadjuvant activity of liposomes to associated antigens may be enhanced 
further by the incorporation of immunomodulators. Studies carried out with 
endotoxin and lipid A show an enhanced adjuvant effect to the antigen in association 
with liposomes (van Rooijen and van Nieuwmegen, 1980c; Dancey et al., 1977). 
However, further increase in the adjuvant activity is observed when the antigen and the 
immunomodulator are incorporated in the same liposomes.
Another compound possessing immune potentiating activity is N-acetylmuramyl-L- 
alanyl-D-isoglutamine [muramyl dipeptide (MDP)] the minimal structural unit that 
can replace the immunoadjuvant activity of mycobacteria in CFA. Encapsulation of 
MDP in liposomes enhances its effectiveness in producing an immune response against 
antigen compared to the unencapsulated MDP (Chedid et al., 1979). In addition, 
encapsulation of M D P in liposomes reduces the amount of drug needed for protection
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against infections (Fraser-Smith et al., 1983). Liposome-encapsulated MDP has been 
found to activate macrophages more efficiently in vitro than free MDP (Sone and 
Fidler, 1981). This property to activate macrophages has been further extended in vivo 
for the destruction of spontaneous lymph mode and visceral metastasis (Fidler et al., 
1981). A more specific mediator involved in the activation of normal noncytotoxic cells 
of the macrophage-histocyte series to become cytotoxic against tumour cells is the 
soluble lymphokine referred to as macrophage-activating factor (MAF) (Churchill et 
al., 1975). However, the in vivo administration of MAF to bring about systemic 
activation of macrophages has not been accomplished. Lymphokines have a short life 
and after injection into circulation they rapidly bind to serum proteins. Moreover, 
preparations of MAF are antigenic and therefore their repeated injections may not be 
possible. Encapsulation of MAF in liposomes prevents these undesirable side effects at 
the same time induces an efficient macrophage activation (Kleinerman et al., 1983).
 
Concluding remarks 
 
The recent development in liposome research demonstrate the promising role of 
liposomes in immunology, in particular, as immunopotentiators and carriers of 
antigens. The major factors affecting the immunoadjuvant action of liposomes appear 
to be the charge of the vesicles and the site of association of the antigen with the lipid 
bilayer. The presence of sugar ligands on the surface of liposomes, further seem to 
regulate the production of antibodies to the associated antigens. However, for a clear 
understanding of the mechanism of action of liposomes further investigations are 
required. Still, the potential value of liposomes as immunological adjuvants has 
emerged as one of the brightest prospects among the many projected clinical 
applications of liposomes.
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